Literature DB >> 14676068

Severe hidradenitis suppurativa treated with infliximab infusion.

David R Adams1, Kenneth B Gordon, Attila G Devenyi, Michael D Ioffreda.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14676068     DOI: 10.1001/archderm.139.12.1540

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


× No keyword cloud information.
  5 in total

1.  A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.

Authors:  Robert A Lee; Erica Dommasch; James Treat; Joslyn Sciacca-Kirby; Samuel Chachkin; Jennifer Williams; Daniel B Shin; James J Leyden; Carmela Vittorio; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2009-01-31       Impact factor: 11.527

2.  HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.

Authors:  A B Kimball; J M Sobell; C C Zouboulis; Y Gu; D A Williams; M Sundaram; H D Teixeira; G B E Jemec
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-07-22       Impact factor: 6.166

Review 3.  Systematic review of immunomodulatory therapies for hidradenitis suppurativa.

Authors:  Shi Yu Derek Lim; Hazel H Oon
Journal:  Biologics       Date:  2019-05-13

Review 4.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

5.  Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review.

Authors:  Muskaan Sachdeva; Patrick Kim; Asfandyar Mufti; Khalad Maliyar; Cathryn Sibbald; Afsaneh Alavi
Journal:  J Cutan Med Surg       Date:  2021-09-29       Impact factor: 2.092

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.